AbbVie says schizophrenic drug fails in 2 mid-stage experimental trials
AbbVie Inc.’s two mid-stage trials of an investigational schizophrenia drug have failed to meet its primary goal, according to a company statement.
Drugs
Health
Pharma
Drugs
Health
Pharma
Neurocine’s mid-stage trial drug cuts schizophrenia severity symptoms
US-based Neurocrine Biosciences’ trial drug for treating schizophrenia reduced the severity of the disease symptoms in a mid-stage study of 210 adult participants.